← All companies

Kyverna Therapeutics

Healthcare & Life Sci

Company overview

Kyverna Therapeutics is a late-stage clinical biopharmaceutical company founded in 2018. It develops CD19-targeting CAR T-cell therapy for severe autoimmune diseases driven by B cells. Its lead candidate, miv-cel, is in a rolling Biologics License Application submission for stiff person syndrome.

Gilead Sciences has been a strategic partner since January 2020, when it paid $17.5 million upfront as part of a collaboration deal. That backing supports Kyverna's work as it moves candidates through late-stage development. Kyverna Therapeutics is an H-1B sponsor.

Industry
Healthcare & Life Sci
Headquarters
United States

Filters

Create your account

Create an account to save jobs and track applications.